OakChart

Seres Therapeutics Inc

MCRBHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 3:59 PM ET

1.50-0.06 (-3.85%)
2026-11-12 06:15 CET
Market cap
15.29 USD m
Revenue, TTM
2.12 USD m
Net income, TTM
-46.95 USD m
Free cash flow, TTM
-63.97 USD m
EPS diluted, TTM
-4.84
P/E
-
Compare

Price

MCRB against its 20, 50 and 200-day averages
2050200beatmiss
5.0010.0015.00167K334KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MCRBclose 1.5020-day 2.0150-day 3.13200-day 6.561.50

95.0% under the 52-week high of 29.98 on 20 Nov 2025. 52-week low 1.35 on 11 Nov 2026. Last 15 sessions, 70.4% high to low

Volume 3.41× normal · the line is the 50-bar volume average

Profile

MCRB
52-week range, 0% of the way up
1.5529.98

Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.

Employees66
IPOJun 26, 2015
Beta0.57
ATR, 14d0.25
Rel volume3.41
Short float4.39%
Insider own23.57%
Inst own11.22%

Snapshot

6 groups

Valuation

Index-
Market Cap15.29M
Enterprise Value33.53M
Income-46.95M
Sales2.12M
Book/sh2.13
Cash/sh1.72
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees66
IPOJun 26, 2015

Ratios

P/E-
Forward P/E-
PEG-
P/S7.21
P/B0.71
P/C0.87
P/FCF-
EV/EBITDA-
EV/Sales15.82
Quick Ratio1.65
Current Ratio1.65
Debt/Eq1.67
LT Debt/Eq1.08
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.84
EPS next Y-2.50
EPS next Q-0.65
EPS this Y-700.00%
EPS next Y35.03%
EPS next 5Y-
EPS past 3/5Y- -
Sales past 3/5Y-51.99% -52.67%
EPS Y/Y TTM-889.29%
Sales Y/Y TTM505.41%
EPS Q/Q-274.44%
Sales Q/Q68.95%
EarningsNov 04 BMO
EPS/Sales Surpr.-62.19% -90.66%

Ownership

Insider Own23.57%
Insider Trans-0.04%
Inst Own11.22%
Inst Trans-0.81%
ROA-44.85%
ROE-144.35%
ROIC-105.56%
Gross Margin-35.81%
Oper. Margin-3062.92%
Profit Margin-2209.55%
SMA20-25.45%
SMA50-52.05%
SMA200-77.15%
Trades-

Technical

Shs Outstand10.05M
Shs Float7.79M
Short Float4.39%
Short Ratio4.85
Short Interest0.34M
52W High29.98 -95.00%
52W Low1.55 -3.23%
Volatility15.34% 12.03%
ATR (14)0.25
RSI (14)24.38
Beta0.57
Rel Volume3.41
Avg Volume70.60K
Volume240,398

Performance

Perf Week-28.23%
Perf Month-40.71%
Perf Quarter-66.52%
Perf Half Y-80.67%
Perf YTD-89.92%
Perf Year-89.93%
Perf 3Y-92.61%
Perf 5Y-99.01%
Perf 10Y-99.39%
Recom1.00
Target Price17.00
Prev Close1.56
Price1.50
Change %-3.85%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Jun 23, 2026InitiatedHH.C. WainwrightBuy$12+700.0%
May 08, 2025DowngradeCChardan Capital MarketsBuy → Neutral$6+300.0%
Oct 24, 2024DowngradeJJP MorganNeutral → Underweight
Jun 26, 2023ResumedOOppenheimerOutperform$12+700.0%
Apr 21, 2023InitiatedJJP MorganNeutral$7+366.7%
Jul 23, 2021DowngradeGGoldmanNeutral → Sell$24 → $7+366.7%
May 18, 2021ResumedGGoldmanNeutral$24+1,500.0%
Mar 05, 2021UpgradeCChardan Capital MarketsNeutral → Buy$30+1,900.0%
Sep 18, 2020DowngradeCChardan Capital MarketsBuy → Neutral$32.50 → $27.50+1,733.3%
Aug 18, 2020InitiatedPPiper SandlerOverweight$40+2,566.7%

Peers

Mkt cap
TickerCompanyMkt cap
ACXPAcurx Pharmaceuticals Inc5.72M
CRMDCorMedix Inc413.10M
JSPRJasper Therapeutics Inc16.37M
MESOMesoblast Ltd ADR1.78B
SPROSpero Therapeutics Inc59.40M
INCYIncyte Corp24.92B
ASMBAssembly Biosciences Inc455.47M
INVAInnoviva Inc1.34B
ATRAAtara Biotherapeutics Inc82.61M
SCYXScynexis Inc33.99M

Insider trading

latest 14 of 18
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Brady KellySee RemarksAug 17 '26Sale4.55642918,679Aug 18 05:33 PM
Shaff Eric D.DirectorAug 17 '26Sale4.552631,19712,499Aug 18 05:27 PM
Henn Matthew RSee RemarksAug 17 '26Sale4.55813697,995Aug 18 05:25 PM
DesRosier ThomasSee RemarksAug 17 '26Sale4.55823738,117Aug 18 05:22 PM
TERESA L YOUNGOfficerMay 19 '26Proposed Sale7.691671,284May 19 04:15 PM
Shaff Eric D.DirectorMay 18 '26Sale7.532591,95012,040May 19 04:05 PM
DesRosier ThomasSee RemarksMay 18 '26Sale7.53795957,954May 19 04:05 PM
Henn Matthew RSee RemarksMay 18 '26Sale7.53775807,838May 19 04:05 PM
Brady KellySee RemarksMay 18 '26Sale7.53594448,562May 19 04:05 PM
TERESA L YOUNGOfficerMar 17 '26Proposed Sale9.128,55377,967Mar 17 04:50 PM
Shaff Eric D.DirectorFeb 15 '26Sale8.472592,19411,577Feb 18 04:30 PM
Young Teresa L.See RemarksFeb 15 '26Sale8.47756358,557Feb 18 04:30 PM
DesRosier ThomasSee RemarksFeb 15 '26Sale8.47786617,789Feb 18 04:30 PM
Henn Matthew RSee RemarksFeb 15 '26Sale8.47897547,677Feb 18 04:30 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWCiShares Micro-Cap ETFAUM: 1.22B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B
EESWisdomTree U.S. SmallCap FundAUM: 684.87M
BUSMEA Bridgeway Ultra-Small Company Market ETFAUM: 111.21M

News

latest 14 of 200
  • Seres Therapeutics: Q3 Earnings Snapshot (Associated Press) +6.63%
  • Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) (GlobeNewswire)
  • Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients (GlobeNewswire) +7.10%
  • Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 (GlobeNewswire)
  • Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.04%
  • Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire) +5.50%
  • Seres Therapeutics: Q2 Earnings Snapshot (Associated Press)
  • Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs (GlobeNewswire)
  • Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment (GlobeNewswire) -12.29%
  • Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (GlobeNewswire)
  • Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 (GlobeNewswire)
  • Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference (GlobeNewswire)
  • Seres Therapeutics: Q1 Earnings Snapshot (Associated Press)
  • Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-1.630-1.005-1.6300.596.352
2026Q22026-08-050.470-2.1850.4700.740.182
2026Q12026-05-05-2.080-1.880-2.0780.36-1
2025Q42026-03-12-1.780-2.110-1.6050.000.003
2025Q32025-11-050.9400.4570.9350.357.833
2025Q22025-08-06-2.270-2.490-2.2710.000.004
2025Q12025-05-073.7500.1023.7500.0010.005
2024Q42025-03-13-1.800-3.930-1.8080.000.006
2024Q32024-11-1311.600-1.550-7.5900.0031.006
2024Q22024-08-13-4.400-5.482-4.3390.00-0.266
2024Q12024-05-08-5.400-6.834-5.4940.000.256
2023Q42024-03-05-6.200-9.932-6.3820.07-0.167
2023Q32023-11-02-7.400-10.028-7.4600.311.507
2023Q22023-08-087.20010.6907.170126.47125.677
2023Q12023-05-09-11.400-11.000-11.310-0.521.587
2022Q42023-03-07-10.200-9.100-10.9880.976.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-24.800-25.534-24.81234.5133.12
2020FY-22.400-22.050-22.34133.2222.59
2021FY-14.400-12.312-14.302144.93149.82
2022FY-46.200-43.276-46.2927.1313.76
2023FY-17.800-19.732-17.769126.33126.07
2024FY0.000-2.399-18.8640.000.00
2025FY0.6400.2630.6400.790.27
2026FY--3.840--8.09
2027FY--2.495--0.42
2028FY--1.900--0.27
2029FY--1.910--0.55
2030FY--1.890--0.55

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-042106.410.3112.50
2026Q4S2026-10-192006.360.2112.50
2026Q4S2026-08-052016.360.2112.50
2026Q4S2026-07-2010012.5012.5012.50
2026Q4S2026-06-1820012.5012.5012.50
2026Q4S2026-05-0510012.5012.5012.50
2026Q4S2026-04-1110012.5012.5012.50
2026Q4S2026-03-121000.000.000.00
2026Q4S2025-12-041000.000.000.00
2026Q4S2025-11-122000.000.000.00
2026Q4S2025-11-112000.000.000.00
2026Q4S2025-11-102000.000.000.00
2026Q4S2025-11-092000.000.000.00
2026Q4S2025-11-082000.000.000.00

Estimate history

EPS, annual-44.193-48.568-24.812-22.341-14.302-46.292-17.769-18.8640.642-4.8443
Period201720182019202020212022202320242025TTM
EPS, quarterly-7.59-1.8083.75-2.2710.935-1.605-2.0780.47-1.632
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual32.128.26734.50533.215144.9277.128000.7892.12
Period201720182019202020212022202320242025TTM
Sales, quarterly00000.3510.4380.3580.7360.593
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual2.0292.0473.5074.5734.5946.2616.7528.659.55610.05
Period201720182019202020212022202320242025MRQ
Shares, quarterly8.518.658.7328.7548.7659.5569.5929.82810.05
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue2.120.790.000.007.13144.9333.2234.5128.27
Cost of Goods Sold Incl. D&A2.894.1314.7015.1111.85----
Gross Profit-0.76-3.34-14.70-15.11-4.72----
Selling, General and Administrative Excl. Other64.3390.63103.35179.98240.76201.93112.4595.06120.69
Research and Development39.6149.0661.87117.60172.92141.8990.5780.1495.95
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-65.09-93.97-118.05-195.10-245.49-66.22-88.13-70.38-100.28
Interest Expense0.000.00-2.476.022.912.920.500.00
Unusual Expense12.620.003.270.000.000.000.001.49-
Net Income Before Taxes-46.955.70-125.77-190.13-250.16-65.58-89.13-70.28-98.94
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-46.955.70-125.77-190.13-250.16-65.58-89.13-70.28-98.94
Net Income From Continuing Operations-46.955.70-125.77-190.13-250.16-65.58-89.13-70.28-98.94
Net Income-46.955.70-146.57-113.72-250.16-65.58-89.13-70.28-98.94
EPS (Recurring)-3.820.64-18.57-17.77-46.29-14.30-22.34-24.44-48.57
EPS (Basic, Before Extraordinaries)-4.840.64-18.86-17.77-46.29-14.30-22.34-24.81-48.57
EPS (Diluted)-4.840.64-18.86-17.77-46.29-14.30-22.34-24.81-48.57
EBITDA-62.20-89.84-103.35-179.98-233.63-57.00-79.24-60.55-92.42
Non-Operating Income (Expense)30.7699.67-4.467.431.353.561.932.101.34
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense8.5610.8420.9734.1025.4820.228.828.3416.64
Price To Sales Ratio15.74167.28-1.4284.915.2758.855.666.52
Gross Margin-35.81-423.83---66.29----
Operating Margin-3,062.92-11,910.14---3,443.97-45.70-265.33-203.98-354.77
Net Margin-2,209.55721.93---3,509.50-45.25-268.33-203.68-350.03
Shares Outstanding10.059.568.656.756.264.594.573.512.05
Market Capitalization15.2915.29143.77180.08696.70765.442,240.75241.99185.03

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.590.740.360.440.350.000.000.00
Cost of Goods Sold Incl. D&A0.480.670.780.951.041.061.083.09
Gross Profit0.110.07-0.42-0.52-0.69-1.06-1.08-3.09
Selling, General and Administrative Excl. Other10.5615.3419.5718.8621.7823.8226.1625.74
Research and Development5.599.1413.2011.6812.6212.9411.8212.84
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-10.45-15.27-19.99-19.38-22.48-24.88-27.24-28.84
Interest Expense0.000.000.000.000.000.000.00-
Unusual Expense5.716.000.910.000.000.000.000.00
Net Income Before Taxes-16.294.58-19.91-15.348.20-19.8632.68-15.64
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-16.294.58-19.91-15.348.20-19.8632.68-15.64
Net Income From Continuing Operations-16.294.58-19.91-15.348.20-19.8632.68-15.64
Net Income-16.294.58-19.91-15.348.20-19.8632.68-15.64
EPS (Recurring)-1.230.90-2.01-1.600.94-2.273.75-1.81
EPS (Basic, Before Extraordinaries)-1.630.47-2.08-1.600.94-2.273.76-1.81
EPS (Diluted)-1.630.47-2.08-1.600.94-2.273.75-1.81
EBITDA-9.97-14.60-19.21-18.42-21.43-23.82-26.16-25.74
Non-Operating Income (Expense)-0.1325.850.994.0430.685.0359.9213.20
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.861.741.773.202.482.342.827.38
Price To Earnings Ratio--10.9524.51----
Price To Sales Ratio15.7440.8474.10180.23480.81---
Gross Margin18.898.97-118.16-117.81-197.44---
Operating Margin-1,761.72-2,074.73-5,584.64-4,423.97-6,403.70---
Net Margin-2,746.37622.42-5,562.29-3,501.142,337.32---
Shares Outstanding10.059.839.599.568.768.758.738.65
Market Capitalization15.2976.4185.03134.61168.4497.02122.27143.77

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments45.7730.79127.97181.34290.71253.6294.8285.82149.98
Short Term Receivables0.522.070.000.000.009.391.780.000.00
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.095.8147.4513.4212.925.773.596.845.09
Total Current Assets49.3838.67175.41194.76303.63268.78100.1992.67155.08
Net Property, Plant & Equipment80.1292.44108.03133.9736.1522.9430.8526.2932.93
Total Investments and Advances8.678.679.599.599.9051.231.401.511.51
Intangible Assets-----0.000.000.000.00
Other Assets0.030.0365.5710.465.190.000.000.000.00
Total Assets138.19139.81358.60348.78354.86342.94132.44120.47189.52
Short Term Debt Incl. Current Port. of LT Debt10.398.675.594.066.615.574.460.000.00
Accounts Payable1.684.083.6417.4413.734.024.866.427.03
Other Current Liabilities7.2528.4789.4364.1061.9136.8336.6835.6324.59
Total Current Liabilities19.3241.2298.6685.6082.2646.4145.9942.0431.62
Long Term Debt72.5882.97193.20158.5342.6035.2040.320.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities2.081.84111.6093.8798.4986.5894.45126.4897.20
Total Liabilities93.97126.03403.46338.00223.35168.19180.76168.52128.82
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity44.2213.78-44.8610.78131.51174.75-48.32-48.0560.70
Total Shareholders Equity44.2213.78-44.8610.78131.51174.75-48.32-48.0560.70
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity44.2213.78-44.8610.78131.51174.75-48.32-48.0560.70
Total Liabilities & Stockholders Equity138.19139.81358.60348.78354.86342.94132.44120.47189.52
Book Value Per Share4.631.59-6.641.7228.6238.21-13.78-23.4729.92
Tangible Book Value Per Share4.631.59-6.641.7228.6238.21-13.78-23.4729.92
Full-Time Employees66103233431333155108145138
Price to Book Ratio0.7110.43-11.9110.315.8212.82-5.01-3.854.80
Return on Assets4.10-50.47-53.76-71.10-18.80-37.50-55.58-63.83-38.68
Return on Equity19.64---351.62-42.83-140.99--1,563.81-92.46
Return on Invested Capital4.88-151.49-76.66-147.75-37.67-42.45---147.25
Quick Ratio2.560.941.782.283.695.792.182.204.90
Current Ratio2.560.941.782.283.695.792.182.204.90

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-46.955.700.14-113.72-250.16-65.58-89.13-70.28-98.94
Depreciation2.894.1314.7015.1111.859.228.897.607.86
Other Funds (Non Cash)2.5919.07-97.9340.2327.8821.519.8210.3616.43
Funds from Operations-41.4728.90-83.10-58.38-210.43-34.84-70.41-52.32-74.65
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-22.47-27.78-65.51-58.98-18.3941.53-23.20-24.6311.80
Cash from Operating Activities-63.941.12-148.61-117.35-228.826.69-93.61-76.94-62.85
Capital Expenditures-0.03-0.25-0.38-7.97-9.82-9.57-0.59-1.00-1.94
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.280.210.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.00142.6718.5692.2573.65-158.30-29.52114.25
Purchase of Investments0.000.000.00-4.43-48.22-95.97-218.28-46.42-21.83
Sale Or Maturity of Investments0.000.00142.6722.98140.47169.6259.9816.90136.09
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources12.500.000.000.000.000.000.000.000.00
Cash from Investing Activities12.75-0.04142.2910.5882.4364.09-158.89-30.52112.32
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock15.5513.9024.0221.19103.902.13303.4261.660.27
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.00-0.20
Sale of Common Pref Stock15.5513.9024.0221.19103.902.13303.4261.660.47
Proceedsfrom Stock Options15.0313.1723.5318.16101.170.00288.5461.220.06
Issuance or Reduction of Debt, Net0.000.00-127.9150.5225.70-0.950.0025.000.00
Change in Long Term Debt0.000.000.000.000.000.000.0025.000.00
Issuance of Long Term Debt0.000.000.000.000.000.000.0025.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.0013.520.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities15.5513.90-90.3771.70129.601.18303.4286.660.27
Exchange Rate Effect-0.00-0.000.00-0.00----
Net Change in Cash-35.6414.97-96.69-35.06-16.7971.9550.92-20.8149.73
Free Cash Flow-63.970.86-148.99-125.33-238.64-2.88-94.20-77.95-64.79
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow-152.58-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments17.5315.5929.8345.7747.6445.38
Short Term Receivables12.6825.270.230.520.780.88
Inventories0.000.000.000.000.000.00
Other Current Assets4.211.481.773.093.112.42
Total Current Assets34.4242.3531.8449.3851.5348.69
Net Property, Plant & Equipment30.6656.9777.0880.1283.2586.42
Total Investments and Advances0.772.248.678.678.678.67
Other Assets0.030.030.030.030.030.03
Total Assets65.89101.59117.62138.19143.47143.80
Short Term Debt Incl. Current Port. of LT Debt12.6511.8310.8710.399.929.48
Accounts Payable1.461.192.341.681.682.20
Other Current Liabilities6.787.026.147.2510.8319.26
Total Current Liabilities20.8920.0319.3419.3222.4330.94
Long Term Debt23.1244.8269.6372.5875.3377.96
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.512.212.142.082.011.95
Total Liabilities44.5367.0591.1293.9799.78110.85
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity21.3634.5326.5044.2243.7032.95
Total Shareholders Equity21.3634.5326.5044.2243.7032.95
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity21.3634.5326.5044.2243.7032.95
Total Liabilities & Stockholders Equity65.89101.59117.62138.19143.47143.80
Book Value Per Share2.133.512.764.634.993.76
Tangible Book Value Per Share2.133.512.764.634.993.76
Full-Time Employees---66--
Price to Book Ratio0.712.861.922.985.111.92
Return on Assets-44.85-18.31-33.294.103.35-23.13
Return on Equity-144.35-66.57-121.8719.6415.95-
Return on Invested Capital-36.615.77-20.71-13.136.89-17.90
Quick Ratio1.652.111.652.562.301.57
Current Ratio1.652.111.652.562.301.57

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-16.294.58-19.91-15.348.20-19.86
Depreciation0.480.670.780.951.041.06
Other Funds (Non Cash)-16.259.634.025.194.614.40
Funds from Operations-32.0614.88-15.11-9.1913.86-14.39
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital21.58-37.28-1.25-5.52-11.651.10
Cash from Operating Activities-10.48-22.39-16.36-14.712.21-13.29
Capital Expenditures0.000.000.00-0.03-0.01-0.18
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.050.010.000.210.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources12.500.000.000.000.000.00
Cash from Investing Activities12.550.010.000.18-0.01-0.18
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.751.720.4312.660.060.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.751.720.4312.660.060.00
Proceedsfrom Stock Options0.741.720.4012.170.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities0.751.720.4312.660.060.00
Net Change in Cash2.83-20.66-15.93-1.872.26-13.47
Free Cash Flow-10.48-22.39-16.36-14.742.20-13.47
Price to Free Cash Flow---164.39--

Revenue breakdown

Pharmaceutical Preparations2025: 789.00K
United States2025: 789.00K

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-304.39%0.3M7.8M69.02K
2026-10-154.11%0.3M7.6M64.66K
2026-09-304.17%0.3M7.5M73.92K
2026-09-154.00%0.3M7.5M83.47K
2026-08-314.73%0.4M7.5M91.60K
2026-08-144.89%0.4M7.5M87.35K
2026-07-314.18%0.3M7.5M84.34K
2026-07-154.13%0.3M7.3M86.35K
2026-06-302.14%0.2M7.3M67.47K
2026-06-152.99%0.2M7.3M56.56K
2026-05-296.53%0.5M7.3M46.54K
2026-05-157.00%0.5M7.3M51.55K
2026-04-307.43%0.5M7.3M69.17K
2026-04-158.08%0.6M7.2M65.25K
2026-03-318.40%0.6M7.1M66.44K
2026-03-138.84%0.6M7.1M70.75K
2026-02-279.76%0.7M6.7M79.59K
2026-02-1311.54%0.8M6.7M157.84K
2026-01-3012.32%0.8M6.7M147.65K
2026-01-1513.03%0.9M6.7M155.19K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.500.000.050.062.5056600.000.173-0.0080.001
call5.000.000.100.044.9354230.000.118-0.0130.000
call7.500.000.250.006.2710.000.000.109-0.0140.000
put2.500.003.200.550.0003030.00-0.828-0.0090.001
put5.001.404.901.6026.9806.000.00-0.882-0.0120.000
put7.504.907.500.000.0000.000.00-0.895-0.0140.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-10-268-KCurrent report2026-10-22SEC
2026-08-21EFFECTEffectiveness filing by commission orderSEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-184Statement of changes in beneficial ownership of securities2026-08-15SEC
2026-08-13S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-048-KCurrent report2026-07-31SEC
2026-08-04424B5SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-104Statement of changes in beneficial ownership of securities2026-07-08SEC
2026-07-09S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-088-KCurrent report2026-07-08SEC
2026-07-088-KCurrent report2026-07-08SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-024Statement of changes in beneficial ownership of securities2026-07-01SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-08002.23K4
2026-070000
2026-060000
2026-05003.57K4
2026-040000
2026-030000
2026-02004.24K4
2026-010000
2025-120000
2025-110044.84K4

Institutional holders

Manager% owned
Flagship Pioneering, LLC11.94%
VANGUARD CAPITAL MANAGEMENT LLC2.97%
MARSHALL WACE, LLP1.78%
Vontobel Holding Ltd.1.15%
BlackRock, Inc.1.15%
GEODE CAPITAL MANAGEMENT, LLC0.79%
SUSQUEHANNA INTERNATIONAL GROUP, LLP0.60%
VANGUARD FIDUCIARY TRUST CO0.50%
STATE STREET CORP0.35%
Lion Point Capital, LP0.33%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.13%
VANGUARD EXTENDED MARKET INDEX FUND0.78%
Fidelity Extended Market Index Fund0.40%
Avantis U.S. Small Cap Value ETF0.39%
Schwab U.S. Small-Cap ETF0.31%
iShares Micro-Cap ETF0.26%
Goldman Sachs Absolute Return Tracker Fund0.24%
Fidelity Total Market Index Fund0.14%
Invesco RAFI US 1500 Small-Mid ETF0.13%
Fidelity Series Total Market Index Fund0.10%

OakChart. MCRB. Cached 15 minutes.